Silexion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2013	FY 2012
Period Ending	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Net Income	-1.36	-0.94
Depreciation & Amortization	0	0
Stock-Based Compensation	0.42	0.04
Change in Accounts Receivable	0.06	-0.1
Change in Accounts Payable	0.02	0.06
Change in Other Net Operating Assets	0.05	0.03
Operating Cash Flow	-0.79	-0.91
Capital Expenditures	-0.01	-0
Other Investing Activities	-0.01	-0.03
Investing Cash Flow	-0.02	-0.03
Issuance of Common Stock	-	1.72
Financing Cash Flow	-	1.72
Net Cash Flow	-0.81	0.78
Free Cash Flow	-0.8	-0.91
Free Cash Flow Per Share	-48.23	-64.06
Levered Free Cash Flow	-0.31	-
Unlevered Free Cash Flow	-0.3	-
Change in Net Working Capital	-0.12	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q